On October 17, 2019 Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, reported the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases (Press release, Kymera Therapeutics, OCT 17, 2019, View Source [SID1234542348]). Data will be shared during a poster presentation (Abstract #C054) at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) in Boston on Tuesday, October 29 at 12:30 PM EST.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
STAT3 is an oncogenic transcription factor that is regulated by multiple signaling events including the IL-6-JAK pathway and growth factor receptors. Activating mutations and aberrant activation of STAT3 have been directly linked to the promotion of cancer cell survival and proliferation and immune evasion, making it a highly attractive target for hematologic malignancies and solid tumors.
"STAT3 has historically been considered an ‘undruggable’ transcription factor. Over the past few decades, some of the key challenges for this target have been the lack of small molecule binders, additional functions beyond transcriptional regulation, and sequence homology with other SH2 domain-containing STAT family members," said Nello Mainolfi, PhD, Founder, President & CSO of Kymera Therapeutics. "Using our drug discovery engine, especially our understanding of ternary complex structure and function, we rationally designed specific STAT3 degraders with excellent in vivo properties. Our data using these degraders have shown disruption of signaling downstream of STAT3 and promising antitumor activity in multiple cancer models, supporting the transformative therapeutic potential of this modality. With these unique molecules we are expanding the understanding of the biological impact of STAT3 degradation in tumor and immune contexts."
AACR-NCI-EORTC Study Highlights
ABSTRACT #C054, "Discovery of KYM-003, a Potent and Selective STAT3 Degrader with Anti-Tumor Activity in Heme Malignancies," presented by Fred Csibi, Associate Director, Oncology Biology at Kymera Therapeutics.
in vitro
KYM-003 cooperatively formed a high-affinity STAT3-KYM003-E3 ligase ternary complex.
KYM-003 potently induced ubiquitination of endogenous STAT3.
KYM003-induced degradation was highly selective for STAT3 versus >10,000 other detected proteins (including all other STAT family members) in tumor cell lines and hPBMCs.
KYM003-induced degradation of STAT3 resulted in downregulation of STAT3 target-gene expression, including the PIM1 oncogene.
in vivo
Total STAT3 levels in tumors were reduced by >90% for at least 24 hours after a single dose of KYM-003.
Repeated dosing of KYM-003 showed dose-dependent antitumor activity in xenograft models of heme malignancies with good tolerability.